SGLT2 inhibitors were less frequently prescribed in the CKD group (20.6% vs. 35.2%; p < 0.001), although this particular drug use was analyzed only for the last 7 years of the study period, since SGLT2 inhibitors began to be prescribed from 2018 onward. The gene discussed is SLC5A2; the disease is chronic kidney disease.